Pharming Group N.V. Files 6-K with Press Release

TL;DR

Pharming Group (PHAR) filed a 6-K on 4/8, likely with news. Check Exhibit 99.1.

AI Summary

Pharming Group N.V. filed a Form 6-K on April 8, 2024, to furnish a press release dated April 8, 2024, as Exhibit 99.1. The filing does not contain specific financial figures or operational details beyond the submission of this press release.

Why It Matters

This filing indicates Pharming Group N.V. is providing updated information to the SEC, likely containing important business or financial developments for investors.

Risk Assessment

Risk Level: low — This filing is a routine submission of a press release and does not contain inherently risky information.

Key Players & Entities

• Pharming Group N.V. (company) — Registrant
• 001-39822 (company) — SEC File Number
• April 8, 2024 (date) — Filing Date and Press Release Date

FAQ

From the Filing

0001828316-24-000012.txt : 20240408 0001828316-24-000012.hdr.sgml : 20240408 20240408061533 ACCESSION NUMBER: 0001828316-24-000012 CONFORMED SUBMISSION TYPE: 6-K PUBLIC DOCUMENT COUNT: 3 CONFORMED PERIOD OF REPORT: 20240408 FILED AS OF DATE: 20240408 DATE AS OF CHANGE: 20240408 FILER: COMPANY DATA: COMPANY CONFORMED NAME: Pharming Group N.V. CENTRAL INDEX KEY: 0001828316 STANDARD INDUSTRIAL CLASSIFICATION: PHARMACEUTICAL PREPARATIONS [2834] ORGANIZATION NAME: 03 Life Sciences IRS NUMBER: 000000000 STATE OF INCORPORATION: P7 FISCAL YEAR END: 1231 FILING VALUES: FORM TYPE: 6-K SEC ACT: 1934 Act SEC FILE NUMBER: 001-39822 FILM NUMBER: 24828038 BUSINESS ADDRESS: STREET 1: DARWINWEG 24 CITY: LEIDEN STATE: P7 ZIP: 2333 CR BUSINESS PHONE: 31 (0)71 5247 400 MAIL ADDRESS: STREET 1: DARWINWEG 24 CITY: LEIDEN STATE: P7 ZIP: 2333 CR FORMER COMPANY: FORMER CONFORMED NAME: Pharming Group Group N.V. DATE OF NAME CHANGE: 20201014 6-K 1 pharmingped1completionofen.htm 6-K Document UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 6-K REPORT OF FOREIGN PRIVATE ISSUER PURSUANT TO RULE 13a-16 OR 15d-16 UNDER THE SECURITIES EXCHANGE ACT OF 1934 For the Month of April 2024 Commission File Number: 001-39822 Pharming Group N.V. (Exact Name of Registrant as Specified in Its Charter) Darwinweg 24 2333 CR Leiden The Netherlands (Address of principal executive offices) Indicate by check mark whether the registrant files or will file annual reports under cover of Form 20-F or Form 40-F. Form 20-F ☒ Form 40-F ☐ Indicate by check mark if the registrant is submitting the Form 6-K in paper as permitted by Regulation S-T Rule 101(b)(1): ☐ Indicate by check mark if the registrant is submitting the Form 6-K in paper as permitted by Regulation S-T Rule 101(b)(7): ☐ Furnished as Exhibit 99.1 to this Report on Form 6-K is a press release of Pharming Group N.V., or the Company, dated April 8, 2024. EXHIBIT INDEX Exhibit No. Description 99.1 Pharming announces completion of enrollment in pediatric clinical trial of leniolisib SIGNATURE Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned, thereunto duly authorized. Pharming Group N.V. By: /s/ Sijmen de Vries Name: Sijmen de Vries Title: CEO Date: April 8, 2024 Pharming announces completion of enrollment in pediatric clinical trial of leniolisib This multinational Phase III study is evaluating leniolisib tablets in children aged 4 to 11 years with APDS, a rare primary immunodeficiency Leiden, the Netherlands, April 8, 2024: Pharming Group N.V. (“Pharming” or “the Company”) (EURONEXT Amsterd am: PHARM/Nasdaq: PHAR) announces the completion of patient enrollment in its Phase III clinical trial (NCT05438407) evaluating the investigational drug leniolisib, an oral, selective phosphoinositide 3-kinase delta (PI3Kδ) inhibitor, in children aged 4 to 11 years with activated phosphoinositide 3-kinase delta syndrome (APDS). Leniolisib, marketed under the brand name Joenja® in the U.S., received approval from the US Food and Drug Administration (FDA) for the treatment of APDS in adult and pediatric patients 12 years of age and older in March 2023. Pharming plans to include data from this 4–11-year-old trial in regulatory filings worldwide for the approval of leniolisib for pediatric patients with APDS, beginning in 2025. Anurag Relan, MD, MPH, Chief Medical Officer of Pharming, commented:   “This is the first clinical trial for younger pediatric patients with APDS, who have a significant unmet need for a disease modifying treatment. I am pleased with the progress made in our Phase III pediatric clinical program evaluating leniolisib in children with APDS. By intervening at a younger age, we may help prevent patients from developing immune-related complications that are li